Overview

R2 in the Treatment of Follicular Lymphoma

Status:
Unknown status
Trial end date:
2020-11-01
Target enrollment:
Participant gender:
Summary
Lenalidomide Based Immunotherapy in the Treatment of FL
Phase:
Phase 2
Details
Lead Sponsor:
Ruijin Hospital
Treatments:
Lenalidomide